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MAPKSignalling by members of the FGF family is required for induction and maintenance of the mesoderm during
amphibian development. One of the downstream effectors of FGF is the SRF-interacting Ets family member
Elk-1, which, after phosphorylation by MAP kinase, activates the expression of immediate–early genes. Here,
we show that Xenopus Elk-1 is phosphorylated in response to FGF signalling in a dynamic pattern throughout
the embryo. Loss of XElk-1 function causes reduced expression of Xbra at neurula stages, followed by a
failure to form notochord and muscle and then the partial loss of trunk structures. One of the genes regulated
by XElk-1 is XEgr-1, which encodes a zinc ﬁnger transcription factor: we show that phosphorylated XElk-1
forms a complex with XSRF that binds to the XEgr-1 promoter. Superﬁcially, Xenopus tropicalis embryos with
reduced levels of XEgr-1 resemble those lacking XElk-1, but to our surprise, levels of Xbra are elevated at late
gastrula stages in such embryos, and over-expression of XEgr-1 causes the down-regulation of Xbra both in
whole embryos and in animal pole regions treated with activin or FGF. In contrast, the myogenic regulatory
factor XMyoD is activated by XEgr-1 in a direct manner. We discuss these counterintuitive results in terms of
the genetic regulatory network to which XEgr-1 contributes.
Crown Copyright © 2009 Published by Elsevier Inc. All rights reserved.Introduction
The mesoderm of the amphibian embryo is induced by signals
derived from the vegetal hemisphere of the embryo during blastula
and gastrula stages (Smith, 1995). Current thinking has it that
mesoderm-inducing molecules are members of the transforming
growth factor type β (TGF-β) family and that mesodermal gene
expression is maintained by members of the ﬁbroblast growth factor
(FGF) family (Heasman, 1997; Heasman, 2006). For example,
maintenance of Xbra expression in Xenopus is thought to occur
through a loop in which FGF signalling activates the expression of
Xbra and Xbra then directly activates expression of the FGF family
member eFGF (Isaacs et al., 1994; Kroll and Amaya, 1996; Schulte-
Merker and Smith, 1995). Recent experiments suggest that FGF
signalling is also necessary for the establishment of Xbra expression
(Fletcher and Harland, 2008), but the questions remain: how is this
simple autocatalytic feed-forward loop kept in check, and what other
components play a role in modulating mesoderm formation in
response to FGF? The answers to these questions requires identiﬁca-
tion of other components of the FGF signal transduction pathway and
elucidation of the genetic regulatory network (Alon, 2007; DavidsonNational Institute for Medical
K.
h).
09 Published by Elsevier Inc. All rigand Erwin, 2006; Levine and Davidson, 2005) that is initiated by FGF
signalling.
FGF family members signal through receptor tyrosine kinases. The
receptors go on to activate several signal transduction pathways,
prominent amongst which is theMAP kinase pathway, which includes
molecules such as Ras, Raf, Mek and Erk, all of which, in Xenopus,
display loss-of-function phenotypes similar to that of FGF (Gotoh
et al., 1995; LaBonne et al., 1995; Umbhauer et al., 1995). One
target of MAP kinase is the SRF-interacting Ets transcription factor
Elk-1 (Gille et al., 1995; Hipskind et al., 1994; Sharrocks, 1995),
which activates immediate–early genes such as Egr-1, whose
product is a transcription factor that can act both as a repressor
and as an activator of transcription (Bahouth et al., 2002; Chapman
and Perkins, 2000; Lemaire et al., 1990; Wang et al., 2005).
Although a dominant-negative derivative of human Elk-1 is known
to block the induction of XEgr-1 by FGF in isolated animal pole regions
(Panitz et al., 1998), no Xenopus homologue of Elk-1 has yet been
isolated and its function has not been analyzed. Thus, in the ﬁrst part
of this paper we show that Xenopus Elk-1 (XElk-1) is expressed
ubiquitously in the early Xenopus embryo, but that the phosphory-
lated form of the protein is enriched in the dorsal marginal zone.
Interference with XElk-1 activity causes embryos to resemble those in
which FGF signalling has been disrupted; in particular, they are
truncated posteriorly and muscle and notochord differentiation are
compromised. In addition, expression of XEgr-1 is down-regulated.hts reserved.
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and it is expressed, like Xbra (Smith et al., 1991), throughout the
marginal zone of the embryo (Panitz et al., 1998). Surprisingly,
although XEgr-1 and Xbra are co-expressed, over-expression of XEgr-1
inhibits both the endogenous expression of Xbra and its expression in
animal pole regions in response to activin or FGF. However, XEgr-1 is
not a general repressor ofmesoderm formation because it can activate,
in a direct fashion, the expression of the myogenic regulatory gene
XMyoD. We discuss our results in terms of a genetic regulatory
network consisting of modiﬁed incoherent feed-forward loops (Alon,
2007) involving eFGF, XEgr-1, Xbra and XMyoD.
Materials and methods
Xenopus embryo manipulations
Xenopus laevis embryos were obtained by in vitro fertilization
(Smith, 1993) and staged according to Nieuwkoop and Faber (1975).Fig. 1. Spatiotemporal distribution of XElk-1mRNA and protein. (A) Schematic representatio
transcripts are maternally expressed and are present throughout early development. Thes
deviations of technical replicates of a single experiment. (C) Spatial distribution of XElk-1
expression in notochord and somitic mesoderm. (D) Comparison of the amino acid sequenc
human serine 383, which is phosphorylated byMAP kinase. (E)Western blot analysis of XElk
injected with 400 pg myc-tagged XElk-1 mRNA were treated with 200 ng/ml bFGF for the
phosphorylated XElk-1 (α-pElk-1) or a pan-Elk-1 antibody (α-Elk-1). Levels of phosphorylat
1999; Krain and Nordheim, 1999) but decline by 45 min unless bFGF is present. (F–J) Imm
Xenopus embryos at the early gastrula stage. Control embryos incubated in the absence of pri
Use of an antibody directed against phosphorylated XElk-1 protein reveals staining in nucl
vicinity of the dorsal blastopore lip (arrow, G). (H–J) Whole mount immunocytochemistry sh
(J) stages. pXElk-1 is enriched in the dorsal midline and extends towards the presumptive f
pXElk-1 are present in the presomitic mesoderm (arrow, J).Xenopus tropicalis experiments were carried out as described (Rana
et al., 2006). Antisense morpholino oligonucleotides (MOs) were from
GeneTools (Philomath, OR, USA). They were dissolved in distilled
water and stored at −80°C. Sequences were as follows: XtElk-1 MO:
5′-TCCATGACTGCGGGAGCAAAGAGAC-3′; XtEgr-1 MO1: 5′-CCCTAAGG-
GTGAATGGTGCTGCCGC-3′; XtEgr-1 MO2: 5′-GCTTGGCACAGTGAGGG-
GAGACAGG-3′; Control MO 5′-CCTCTTACCTCAGTTACAATTTATA-3′.
Animal cap assays and growth factor treatments were carried out as
described (Smith, 1993). Explants in which protein synthesis was
inhibited were pre-treated for 20 min in 10 μM cycloheximide before
application of additional factors (2 μM dexamethasone; 25 U/ml
activin).
Constructs
All PCR ampliﬁcations for plasmid construction were carried out
using Pfu DNA polymerase and conﬁrmed by sequencing. The coding
sequence of XElk-1 was isolated by RT-PCR using cDNA from embryosn of XElk-1 functional domains. See text for details. (B) Temporal expression of XElk-1;
e data are representative of two independent experiments. Error bars show standard
mRNA in transverse sections of an albino embryo at the neurula stage reveal XElk-1
es of human (h), Xenopus laevis (Xl) and Xenopus tropicalis (Xt) Elk-1 in the vicinity of
-1 phosphorylation in response to FGF. Animal caps derived from embryos that had been
indicated times and then subjected to western blotting using an antibody speciﬁc for
ed XElk-1 are high at time zero, perhaps as a response to dissection (Christen and Slack,
unocytochemical analysis of phosphorylated XElk-1 protein. (F, G) Sagittal sections of
mary antibody show only non-nuclear staining in cells of the yolky vegetal hemisphere.
ei of the animal hemisphere and of the ventral and dorsal mesoderm, especially in the
owing the distribution of phosphorylated XElk-1 at gastrula (H), neurula (I) and tailbud
orebrain as gastrulation proceeds (arrows, H, I). At the early tailbud stage high levels of
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reverse: 5′-GAATTCATTATGGCTTTTGAAGTCCAGG-3′. The resulting
PCR fragment was cloned into the EcoRV and SpeI sites of pT7TS.
XElk-1mt was created by PCR using 5′-GGACTAGTTCAGGTCCTCCTCG-
GAGATCAGCTTCTGCTCTGGCTTTTGAAGCCCAGG-3′ as reverse primer.
XElk-1-EnR was cloned by excising a BbsI/EcoRI fragment from pT7TS-
XElk-1 and inserting a ClaI/XbaI fragment from Xbra-EnR that had
previously been modiﬁed by insertion of 5 copies of the myc epitope.
ΔEts-EnR was constructed by deleting a BlpI/MspAII fragment from
XElk-1-EnR. All XElk-1 constructs were linearized with XbaI and
mRNA synthesis was carried out using T7 RNA polymerase.
XEgr-1-GRwas constructed by amplifying the XEgr-1 open reading
frame using forward primer 5′-TTTACTAGTCTCCCTAGGGATTCCC-
GAGA-3′ and reverse primer 5′-AAAAAAGCGGCCGCGCAAATCT-
CAATTGTCCTTGG-3′. To create ΔXEgr-1-GR, the reverse primer was
5′-AAAAGCGGCCGCGCAACTCAGAGGGGGGCTCT-3′. The resulting
fragments were cloned into the SpeI/NotI sites of a modiﬁed pSP64T-
GR (Tada et al., 1997).mRNA encoding SRF-VP16 (Dalton and Treisman,
1992) was transcribed from pCS2+SRF-VP16 (Panitz et al., 1998). A
constitutively active (ca) form of Elk-1 (VP16-Elk1) (Hill et al., 1994)
was transcribed from pT7ELKVP16.
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed as described
(Schratt et al., 2004). Two hundred animal caps per sample were
cross-linked in 0.5× MMR, 1% formaldehyde for 15 min. Sonication
was carried out in a volume of 3 ml at 4°C using a microtip and a
Misonix Sonicator 3000. Sonication buffer consisted of 21 mM Tris/
HCl pH 8.0, 3.6mMEDTA, 0.3% SDS, 0.36mMEGTA, 3 μg/ml Aprotinin,
2 μM Pepstatin and 1 mM PMSF. Anti-SRF (Santa Cruz G-20) and anti-
pS383Elk-1 (NEB/CST 9186) antibodies were used at dilutions of
1:500. Incubations were carried out overnight. The equivalent of 25
explants were used in PCR reactions.
Primers used to detect XEgr-1 genomic sequence (AF250346) by
quantitative PCR were as follows. XEgr-1 CArG I forward: 5′-GCTCC-
AGCACCTCATCAGC-3′; reverse: 5′-AGCAGCCATGGATTCTACCG-3′.
XEgr-1 CArG II forward: 5′-CTGGTTCCGAAGGGTTTGC-3′; reverse:
5′-CGTAGCCTTCAATCTCCTCCC-3′. Primers speciﬁc for the XeFGF T-box
site (AF078081) were forward: 5′-AGGCAGAAGTATCACAGCAGT-3′;
reverse: 5′-AATGGGCTCCGTCAGAGCAGA-3′.
Whole mount RNA in situ hybridization embryo sections and
antibody staining
In situ hybridization was performed as described (Harland, 1991;
Steinbach et al., 1998). Plasmids for synthesis of digoxigenin- or FITC-Fig. 2. Impairment of embryonic development by interferencewith Elk-1 activity. (A) The
XElk-1 constructs used in these experiments. Top: myc-tagged XElk-1; middle: myc-
tagged XElk-1-EnR; bottom: ΔEtsXElk-1-EnR. (B) Injection of XElk-1-myc mRNA (0.5 ng
into each cell of the two-cell stage; total 1 ng) has no effect on early Xenopus
development. (C, D) A non-tagged version of XElk-1 also has no effect on development.
Compare C (uninjected) with D (injected). (E–G) Interference with XElk-1 activity by
means of a dominant-interfering construct disrupts Xenopus development. (E) Uninjected
embryos. (F) Embryos injected with 750 pg RNA encoding XElk-1-EnR; such embryos
form a dorsally curved trunk and open neural folds. (G) Embryos injected with 750 pg
RNA encodingΔEtsXElk-1-EnR appear normal. (H–J) Trunk and anterior defects caused by
XElk-1-EnR (I) are rescued, at least partially, by co-expression of X-Elk1 mRNA (J). (K–N)
Notochord (marked by MZ15) and muscle (marked by 12/101) differentiation is
diminished in embryos in which XElk-1 activity is perturbed. Antibody staining was
carried out on 50-μm sections of stage 35 embryos previously injected with 750 pg RNA
encoding XElk-1-EnR. Little notochord can be detected in embryos expressing XElk-1-EnR
(L; compare with control embryo in K). Muscle differentiation is also greatly inhibited (N;
compare with control embryo in M). (O, P) Xbra expression is also greatly inhibited in
embryos injected with 750 pg RNA encoding XElk-1-EnR (O; compare with control
embryos in P). All results were obtained in three independent experiments with over 200
embryos examined per treatment, except for data in panels C and D, which were derived
from two experiments with 60 embryos in each case.labelled antisense RNA probes used were pSP72-Xbra (Smith et al.,
1991), pBKCMV-XEgr-1 (Panitz et al., 1998) and pCS2+XMyoDb
(Wittenberger et al., 1999). Immunocytochemistry was carried out on
whole embryos using polyclonal antibodies against phospho-Ser383-
Elk-1 (NEB/CST 9181) with alkaline phosphatase coupled secondary
antibodies and BM-Purple substrate (Roche). The monoclonal anti-
bodies 12/101 (Kintner and Brockes, 1984) and MZ15 (Smith and
316 O. Nentwich et al. / Developmental Biology 336 (2009) 313–326Watt, 1985; Zanetti et al., 1985) were used as described (Fainsod et al.,
1995), employing an HRP coupled secondary antibody with DAB
substrate (Sigma).
Western blot analysis
Embryos were lysed in lysis buffer as described (Zetser et al.,
2001). Western blotting was carried out following polyacrylamide gel
electrophoresis and used anti-Elk-1 (NEB/CST 9182), anti-pS383Elk-1
(NEB/CST 9181), anti-diphosphorylated ERK 1 and 2 (Sigma M8159)
and anti-pan ERK 1 and 2 (BD Transduction Lab 610123) antibodies.
Electrophoretic mobility shift assay (EMSA)
EMSA was performed as described (Weinhold et al., 2000). In vitro
translated protein was generated using the TnT coupled in vitro
transcription translation system (Promega). Proteins were synthe-
sized from pSR64T-XSRF (Mohun et al., 1991) and pT7TS-XElk-1
templates using SP6 RNA polymerase. Oligonucleotides for EMSA
were as described (Panitz et al., 1998).
Quantitative and semi-quantitative PCR and RT-PCR
RNA preparation, cDNA synthesis and semi-quantitative RT-PCR
were performed as described (Steinbach and Rupp, 1999). Primers
were as follows. Goosecoid forward: 5′-TTCACCGATGAACAACTGGA-3′;
reverse: 5′-TTCCACTTTTGGGCATTTTC-3′; Histone H4 forward: 5′-
CGGGATAACATTCAGGGTATCACT-3′; reverse: 5′-ATCCATGGCGG-
TAACTGTCTTCCT-3′. XElk-1 forward: 5′-CTGTGATTGGCCAGGA-3′;Fig. 3. An antisense morpholino oligonucleotide targeted against X. tropicalis Elk-1 has les
notochord differentiation. (A, C) Embryos injected with a control morpholino oligonucleot
antisense morpholino oligonucleotide directed against XtElk-1. Note delay in blastopore clos
XtElk-1 MO (B) but expression of XtEgr-1 is more signiﬁcantly reduced. (E, F) Expression lev
control MO; (F) an embryo injected with an antisensemorpholino oligonucleotide directed a
(J). (H, K) Embryos injected with an antisense morpholino oligonucleotide targeted against X
of the effects of the MO targeted against XtElk-1. Muscle (I) and notochord (L) formation are
G-L were obtained in three independent experiments. Eighty-ﬁve embryos were injected wit
which 13% appeared normal; and 118 were injected with XtElk-1 MO together with XElk-1reverse: 5′-AACTTCCTATGGCAGAAATGGC-3′; XmAct forward: 5′-GCT-
GACAGAATGCAGAAG-3′; reverse: 5′-TTGCTTGGAGGAGTGTGT-3′.
XMyoDb forward: 5′-AACTGCTCCGATGGCATGATGGATTA-3′; reverse:
5′-ATTGCTGGGAGAAGGGATGGTGATTA-3′. Xmyf5 forward: 5′-
CCCTCAATGGTCTGGAAGAA-3′; reverse: 5′-CGGGGTGATAGAGTCTG-
GAA-3′. XpMes1 forward: 5′-GATTCTGCAGGAGCTGAGGAC-3′; reverse:
5′-GCATGGCAGGGGTACACAGAC-3′.
Quantitative PCR was carried out using Lightcycler 480 Mastermix
(Roche) according to the manufacturer's instructions. Samples were
run in 384-well plates in Lightcycler 480 (Roche) on standard run
templates. Primers were as follows. Histone H4: see above. Xbra
forward: 5′-GAATGAGCTCCAGGCTGGC-3′; reverse: 5′-TCATCTCG-
TTGGTGAGCTCCT-3′. XEgr-1 forward: 5′-ACCATCAAGGCCTATGCAAC-3′;
reverse: 5′-GCAACCATATGGCCTCTCAT-3′. XMyoD forward: 5′-GCTGG-
TTGCTGAATTTCCAT-3′; reverse: 5′-TCAACACAACATTGGCAGGT-3′.
XtBra forward: 5′-AGACATCTTGGATGAGGG-3′; reverse: 5′-GAAGGG-
TACTGACTTGAG-3′.XtODC forward: 5′-GCCATCGTGAAGACTCTCTCCC-3′;
reverse: 5′-TTCGGGTGATTCCTTGCCAC-3′. XtMyoD forward: 5′-AGGT-
CAATGAGGCGTTTGAG-3′; reverse: 5′-CAGAGTCCCCGCTATAATGC-3′.
Results
Identiﬁcation of XElk-1 and spatiotemporal localization of pXElk-1
In an effort to understand the genetic regulatory network that is
initiated and maintained by FGF signalling, we ﬁrst derived a cDNA
encoding Xenopus laevis Elk-1. Comparison of the amino acid
sequence of XElk-1 with its mouse and human orthologues shows
that the four known functional domains of this protein are conserveds effect on gene expression than does XElk-1-EnR but does interfere with muscle and
ide showing expression of Xbra (A) and XtEgr-1 (C). (B, D) Embryos injected with an
ure caused by the MO (compare A and B). Expression of Xbra is only slightly affected by
els of XtMyoD are substantially decreased by XtElk-1 MO. (E) An embryo injected with a
gainst XtElk-1. (G, J) Control embryos at tailbud stages stained with 12/101 (G) orMZ15
tElk-1. Note the reduction in muscle (H) and notochord (K) differentiation. (I, L) Rescue
both restored in embryos injected with XElk-1 mRNA as well as XtElk-1 MO. Results in
h our control MO, of which 90% appeared normal; 109 were injected with XtElk-1MO, of
-myc mRNA, of which 79% appeared normal.
Fig. 4. Binding of XElk-1 to its putative target sequence and analysis of XEgr-1 expression in embryos in which XElk-1 function is perturbed. (A) Binding of XElk-1 to its putative
binding sites in the promoters of XEgr-1 and hc-fos. 32P-labelled double-stranded DNA probes (30,000 cpm) were incubated with in vitro translated proteins. XElk-1 is unable to bind
to DNA on its own (lanes 2 and 7) but forms a ternary complex with XSRF (lanes 4 and 9). This complex can be super-shifted using antibodies recognising Elk-1 (lanes 5, 10). Lanes 1
and 6 were loaded with mock lysates. (B) Positions of the CArG boxes in the XEgr-1 promoter. Arrows indicate the positions of PCR primers for the CArG boxes and for the XEgr-1
open reading frame (ORF). (C) Chromatin immunoprecipitation of endogenous pXElk-1 bound to the XEgr-1 SRE. Chromatin derived from untreated animal caps (ﬁrst four lanes) or
from animal caps treated with 200 ng/ml bFGF (second four lanes) was immunoprecipitated using the indicated antibodies. Samples containing 10% of non-immunoprecipitated
sample material served as input control for sample integrity and PCR (ﬁrst and ﬁfth lanes). Locations of primers are indicated in (B), with primers recognising sequence around the
XeFGF T-Box, which lacks SRF/elk binding sites, serving as a negative control. The weakα-phospho Elk-1 band on the CArG1 element is likely to derive from the activation of theMAP
kinase pathway that occurs following dissection of animal pole regions (Krain and Nordheim, 1999; LaBonne and Whitman, 1997). Bands in the ORF lanes are background. (D) The
structure of SRF-VP16. (E) SRF-VP16 increases XEgr-1 expression at the early gastrula stage. Embryos at the four-cell stage were injected in a single blastomere with mRNA encoding
nuclear β-Gal together with mRNA encoding SRF-VP16, and specimens were processed for in situ hybridization at the early gastrula stage. Development time was adjusted such that
ectopic expression of XEgr-1 (blue) appeared weak enough to allow visualisation of LacZ (red). Note that XEgr-1 is activated in a non-cell-autonomous fashion. (F) The structures of
XElk-1-EnR and of XElk-1ΔEts-EnR-Myc. (G, H) Dominant interfering Elk-1 blocks expression of XEgr-1. Embryos at the four-cell stage were injected in a single blastomere with
mRNA (250 pg) encoding XElk-1-EnR (G) or XElk-1ΔEts-EnR-Myc (H), together with mRNA encoding LacZ. They were ﬁxed at the early gastrula stage and analyzed by in situ
hybridization. LacZ staining appears red. Note that XElk-1-EnR (G), but not XElk-1ΔEts-EnR-Myc (H) causes down-regulation of XEgr1 in a non-cell-autonomous manner. Xbra is also
down-regulated in such experiments (I, J).
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319O. Nentwich et al. / Developmental Biology 336 (2009) 313–326(Fig. 1A). The N-terminal Ets domain (A-box: amino acids 1–90)
mediates DNA binding while the B-box (amino acids 130–153)
interacts with SRF. Transactivation and interaction with MAP kinase
occur at the D-box (amino acids 299–311) and C-box (amino acids
332–382). RT-PCR analysis (Fig. 1B) reveals that XElk-1 is expressed
maternally and that transcripts are present throughout early Xenopus
development. In situ hybridization shows that this expression occurs
throughout the embryo at gastrula and early neurula stages (data not
shown) but is enriched in dorsal mesodermal structures by the late
neurula stage (Fig. 1C).
The induction of immediate–early gene expression by human
Elk-1 involves the phosphorylation of serine 383 by the MAP kinase
Erk-1 (Janknecht et al., 1993). To ask whether the same is true of the
orthologous serine 366 of Xenopus Elk-1 (Fig. 1D), animal pole
regions derived from embryos previously injected with RNA encod-
ing a myc-tagged form of XElk-1 (XElk-1-myc; Fig. 2A) were treated
with bFGF. Protein extracts were analyzed by western blotting using
an antibody speciﬁc for phosphorylated Elk-1. Fig. 1E shows that
bFGF treatment causes signiﬁcant enrichment of levels of phosphor-
ylated XElk-1 within 45 min. Similar results were obtained using an
untagged version of Xelk-1 (Fig. S1). In contrast to Erk-1 (Fig. S1), we
note that a signiﬁcant proportion of Elk-1 is phosphorylated in the
absence of FGF (Figs. 1E and S1). Consistent with this observation,
immunocytochemical analysis detects phosphorylated Elk-1 in the
animal pole region of the Xenopus embryo (Figs. 1F and G), where
levels of FGF signalling are low (Christen and Slack, 1999; Cordenonsi
et al., 2007; LaBonne et al., 1995; Schohl and Fagotto, 2002). The
highest levels of the phosphorylated form of XElk-1 (pXElk-1) are,
however, present in the dorsal marginal zone of the early gastrula
(Fig. 1G). By the late gastrula stage pXElk-1 is enriched in the dorsal
midline (Figs. 1H and I). In early tailbud embryos XElk-1 phosphor-
ylation expands from the closed blastopore towards the presumptive
forebrain and into the presomitic mesoderm (Fig. 1J), overlapping
with domains of MAP kinase activity (Christen and Slack, 1999;
Curran and Grainger, 2000). The spatial and temporal expression
patterns of pXElk-1 differ from those of XElk-1mRNA, suggesting that
the activity of XElk-1 is regulated post-translationally.
Disruption of mesodermal structures caused by XElk-1 loss of function
Over-expression of neither myc-tagged (Figs. 2A and B) nor
untagged (Figs. 2C and D) XElk-1 has any effect on early development
of the Xenopus embryo, consistent with the idea that its activity is
regulated post-translationally. In an effort to inhibit the function of
XElk-1, we ﬁrst created a form of the protein in which the C-terminal
transactivation domain is replaced by the repressor domain of the
Drosophila engrailed protein (Fig. 2A; XElk-1-EnR) (Taylor et al.,
1996). As a control, we also created a version of this protein in which
the Ets domain, which binds DNA, is deleted (Fig. 2A; XElk-1ΔEts-
EnR). Both proteins were tagged with a myc epitope, and wholeFig. 5. Effects of gain and loss of XEgr-1 function on early Xenopus development. (A–D) XEg
injected at the one-cell stage with the indicated doses of XEgr-1mRNA. They were cultured t
XEgr-1 increase, transcription of Xbra decreases. (E–G) Similar experiments reveal that XMyo
expression of both Xbra and XMyoD. (F) An embryo previously injected with XEgr-1 mRNA
embryo previously injected with XEgr-1 mRNA into one blastomere at the four-cell stage sh
and XMyoD in the marginal zone and the ectopic expression of XMyoD in the animal hemisp
26, when formation of muscle and notochord was analyzed using antibodies 12/101 andMZ1
Xenopus tropicalis Egr-1 activity causes elevated levels of Xtbra. X. tropicalis embryos were inj
and neurula stages. Marginal zone expression of Xtbra is unaffected during gastrula stages
embryos (O, S). Loss of X. tropicalis Egr-1 activity causes down-regulation of XtMyoD at th
embryos injected with a control morpholino oligonucleotide (U) but is down-regulated in em
Egr-1 (V, W). (X) Inhibition of X. tropicalis Egr-1 function causes down-regulation of XtMyoD
control morpholino oligonucleotide (Con) or were injected with antisense morpholino oli
expression of XtMyoD at the neurula stage. Note the down-regulation of XtMyoD in embry
embryos injected with XtEgr-1 MO2 (which yields a stronger phenotype than MO1). (Y–
formation. X. tropicalis embryos were injectedwith 30 ng control MO (Y, BB, DD), 30 ng XtEgr
XtEgr-1 display defects in trunk development, which are particularly marked in embryos in
perturbed in such embryos. The ﬁgure shows representative results from three independenmount immunocytochemistry indicated that the two are expressed at
similar levels (data not shown). The phenotypes of embryos injected
with RNA encoding XElk-1-EnR resembled those caused by loss of
function of FGF (Amaya et al., 1993) or of components of the FGF
signal transduction pathway such as Ras, Raf and Erk (LaBonne et al.,
1995; LaBonne andWhitman, 1994; Umbhauer et al., 1995; Whitman
and Melton, 1992). Thus, embryos displayed gastrulation defects (not
shown) and a shortening of the body axis (Figs. 2F and I). No defects
were observed following injection of RNA encoding XElk-1ΔEts-EnR
(Fig. 2G), and the phenotype was partially rescued by co-injection of
RNA encoding wild-type XElk1 (Figs. 2H–J), arguing that the observed
effects are speciﬁc. Muscle and notochord differentiation was
defective (Figs. 2K–N), and expression of Xbra in embryos expressing
XElk-1-EnR declined during neurula stages (Figs. 2O and P), consistent
with the observation that FGF signalling is required for the
maintenance of Xbra. This inhibition of Xbra expression begins at
the early gastrula stage (see Figs. 4I and J).
To conﬁrm the idea that XElk-1 causes developmental defects that
resemble those caused by loss of function of FGF, we turned to antisense
morpholino oligonucleotides (MOs). The genome of the pseudotetra-
ploid species Xenopus laevis contains at least two XElk-1 alleles
(Nentwich and Nordheim, unpublished observation), so to simplify
our analysis we designed an MO directed against the translational start
site of Elk-1 derived from the diploid species X. tropicalis (XtElk-1; see
Materials and methods). Injection of this MO caused a delay in
blastopore closure at the early gastrula stage and a slight decrease in
Xbra and XtEgr-1 expression (Figs. 3A–D). At the late gastrula stage,
expression of XtMyoD was signiﬁcantly reduced (Figs. 3E and F).
At later stages our XtElk-1 antisense morpholino oligonucleotide
caused truncated embryos to form and a disruption of both muscle
(Fig. 3H) and notochord development (Fig. 3K). Our results suggest
that this phenotype is speciﬁc, because it can be partially rescued by
co-injection of XElk-1 mRNA which lacks the morpholino binding site
(Figs. 3I and L). For example, in the case of the notochord, the poorly
deﬁned and fragmented MZ15 staining caused by XtElk-1 MO is
clearly rescued by co-injection of XElk-1 mRNA (Figs. 3K and L).
The MO phenotype is weaker than that caused by injection of
XElk-1-EnR RNA, perhaps because the knock down is incomplete or
perhaps because of persistence of maternal XElk-1 protein (Eisen and
Smith, 2008). It is unlikely that the weaker phenotype is due to
another SRF-interacting factor such as XSap-1 (Nentwich et al., 2001)
substituting for XElk-1 because we do not observe synergistic effects
following co-injection of MOs targeted against XtElk-1 and X.
tropicalis Sap-1 (data not shown).
XElk-1 activates XEgr-1 directly
In previous work we have suggested that a Xenopus homologue of
Elk-1 might activate the zinc ﬁnger-containing transcription factor
XEgr-1, an immediate–early gene expressed in the marginal zone ofr-1 over-expression perturbs transcription of Xbra in the marginal zone. Embryos were
o stage 11 and then analyzed by in situ hybridization for expression of Xbra. As levels of
D is up-regulated in such embryos. (E) An embryo showing the combined endogenous
into one blastomere at the four-cell stage showing down-regulation of Xbra. (G) An
owing the combined expression of Xbra and XMyoD. Note the down-regulation of Xbra
here. (H–K) Embryos injected with 1 ng XEgr-1mRNA were allowed to develop to stage
5, respectively. Over-expression of XEgr-1 causes reduction in both tissues. (L–S) Loss of
ected with 30 ng XtEgr-1 MO2 and analyzed for expression of Xtbra throughout gastrula
(L–N, P–R) but by stage 15 Xtbra is higher in embryos lacking XtEgr-1 than in control
e late gastrula stage. Expression of XtMyoD is normal in uninjected embryos (T) and
bryos injected with antisensemorpholino oligonucleotides directed against X. tropicalis
and up-regulation of Xtbra. Embryos were left uninjected (Uninj), were injected with a
gonucleotides directed against X. tropicalis Egr-1 (MO1, MO2). They were assayed for
os in which XtEgr-1 function is compromised. Expression of Xtbra is up-regulated in
EE) Loss of XEgr-1 function causes trunk defects and perturbs notochord and muscle
-1 MO1 (Z) or 20 ng XtEgr-1MO2 (AA, CC, EE) and cultured to stage 26. Embryos lacking
jected with XtEgr-1 MO2. Muscle (BB, CC) and notochord (DD, EE) differentiation are
t experiments: nN70.
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human Egr-1 gene is a target of MAP kinase, SRF and Elk signalling and
activation of Xenopus Egr-1 by Activin, BMP-4 and XeFGF is inhibited
by a truncated form of Elk-1 that lacks the C and D boxes (Panitz et al.,
1998). The XEgr-1 promoter contains conserved SRF/Elk binding sites
(Panitz et al., 1998) and we show here by means of electrophoretic
mobility shift assays that in the presence of XSRF, in vitro translated
XElk-1 can bind the XEgr-1 serum response element (SRE; Fig. 4A). As
observed with human Elk-1 (Hill et al., 1993) XElk-1 cannot bind the
XEgr-1 SRE in the absence of XSRF (Fig. 4A).
Chromatin immunoprecipitation experiments using antibodies
speciﬁc for SRF and for phosphorylated Elk-1 reveal that pXElk-1
interacts with the XEgr-1 SRE in FGF-treated animal caps whereas in
untreated explants no pXElk-1 can be precipitated from its target
sequence (Fig. 4C lanes 4 and 8). In contrast, XSRF containing
complexes can be precipitated from the XEgr-1 SRE in both FGF-
treated and -untreated animal caps, indicating that XSRF occupies the
XEgr-1 SRE in a constitutive manner (Fig. 4C lanes 3 and 7). One
interpretation of these experiments is that, as in primary ﬁbroblasts
(Li et al., 2003), a complex of XElk-1 and SRF binds its target sequence
in a constitutive manner, and that the complex is activated by
phosphorylation of XElk-1. Unfortunately, we have not been able to
conﬁrm this model becausewe have been unable to precipitate XElk-1
protein from the XEgr-1 SRE using the a pan-Elk-1 antibody.
These results indicate that XSRF and XElk-1 regulate the expression
of XEgr-1 in the early mesoderm. Consistent with this idea, XEgr-1 is
ﬁrst expressed in the dorsal blastopore lip, where levels of pXElk-1 are
highest (Fig. 1G). Furthermore, a constitutively active version of SRF in
which the viral VP16 transactivation domain replaces the C-terminus
of hSRF (SRF-VP16; Fig. 4D) enhances XEgr-1 expression in an
apparently non-cell-autonomous fashion (Fig. 4E). We also ﬁnd,
consistent with the observation that a truncated form of human Elk-
1 prevents the activation of XEgr-1 by XeFGF (Panitz et al., 1998), that
XElk-1-EnR but not XElk-1ΔEts-EnR (Fig. 4F) abolishes expression of
XEgr-1 during gastrula stages (Figs. 4G and H). Such embryos show a
delay in blastopore closure and, interestingly, greater than 90% show
down-regulation of XEgr-1 in a non-cell-autonomous fashion (Fig. 4G),
suggesting there is an additional route by which XElk-1 regulates
XEgr-1. Similar results are observed in embryos injected with SRF-EnR
(data not shown). As described above, we also note that XElk-1-EnR
inhibits the early expression of Xbra (Figs. 4I and J).
XEgr-1 is a negative regulator of Xbra expression
Our results indicate that XElk-1 acts downstream of the FGF
receptor to regulate the expression of XEgr-1 in a direct manner. ToFig. 6. XEgr-1 represses gene activation in response to activin and FGF. (A) Induction of
Goosecoid (Gsc) in response to activin is reduced in animal caps derived from embryos
previously injected with RNA encoding XEgr-1. Animal pole regions were dissected at
stage 8 and 9 and cultured to stage 11 before being assayed by PCR for expression of Gsc
and Histone H4. (B) A hormone-inducible version of XEgr-1 was constructed by fusing
the open reading frame of XEgr-1 to the ligand binding domain of the glucocorticoid
receptor. An XEgr-1-GR fusion lacking the DNA binding and transactivation domains of
XEgr-1 (ΔXEgr-1-GR) served as a negative control. (C) In vitro translation of mRNAs
encoding XEgr-1-GR and ΔXEgr-1-GR demonstrates that they are translated with
similar efﬁciency. (D) XEgr-1 is a direct repressor of FGF-induced Xbra expression.
Animal pole regions derived from embryos previously injected with RNA encoding
either XEgr-1-GR or ΔXEgr-1-GR were treated at stage 9 with bFGF (200 ng/ml),
Dexamethasone (Dex: 2 μM) or Cycloheximide (CHX: 10 μM) as indicated. They were
then analyzed for Xbra expression at stage 11.5. Xbra is activated by bFGF in tissue
expressing ΔXEgr-1-GR in the absence or presence of CHX and Dex, both individually
and in combination. In contrast, Dex treatment of animal pole regions expressing XEgr-
1GR blocks the activation of Xbra even in presence of CHX. (E) Animal caps were treated
as in panel D but with 16 U/ml activin for 2 h instead of bFGF. In tissue expressing
ΔXEgr-1-GR, high levels of Xbra are induced by activin only if CHX is absent, but
signiﬁcant expression does occur in the presence of Dex and CHX (ﬁnal pair of
samples), and this expression is inhibited in animal pole regions expressing XEgr-1-GR.
Note weak induction by cycloheximide alone in the third pair of samples.investigate the function of XEgr-1 during Xenopus development, we
ﬁrst carried out experiments in whole embryos. To our surprise,
because misexpression of FGF causes ectopic expression of Xbra
(Smith et al., 1991), over-expression of XEgr-1 caused down-
regulation of Xbra at gastrula stages (Figs. 5A–D), with such embryos
also showing up-regulation of XMyoD (Figs. 5E–G). By later stages
there seemed to have been some recovery, because although
expression of the muscle-speciﬁc marker 12/101 was reduced, the
notochord-speciﬁc MZ15 was only slightly affected (Figs. 5H–K).
Consistent with the observation that over-expression of XEgr-1
down-regulates expression of Xbra in whole embryos, loss of XEgr-1
function causes a slight up-regulation of Xbra. In these experiments,
two non-overlapping MOs targeting the translation start site of X.
tropicalis Egr-1 (XtEgr-1) mRNA were injected individually into X.
tropicalis embryos at the one-cell stage, and the embryos were
examined by in situ hybridization at stages 10.5, 11, 12 and 15
Fig. 7. Direct regulation of XMyoD by XEgr-1. (A) Direct activation of XMyoD by XEgr-1. Animal pole regions derived from embryos injected with RNA encoding ΔXEgr-1-GR or XEgr-
1-GR were treated at stage 8 with Dex or CHX or both, as indicated.MyoD expression was assayed by quantitative RT-PCR at the equivalent of stage 14. Note that XEgr-1 can activate
MyoD even in the presence of CHX (ﬁnal pair of samples). (B) XEgr-1 can induce premature expression of XMyoD, but not of muscle-speciﬁc actin, Xmyf5 or Xpmes-1. Animal pole
regions derived from embryos injected with RNA encoding XEgr-1-GR, ΔXEgr-1-GR (ΔGR) or Xbra-GR, as indicated, were treated with Dex at stage 8 and assayed for expression of
the indicated genes by semi-quantitative RT-PCR at the indicated stages. For comparison, animal pole regions derived from uninjected embryos were treated with activin at stage 8,
and RNA samples derived from whole embryos (WE) were also assayed. Note low maternal levels of XMyoD at stage 8.5, but also that this gene is activated prematurely in samples
expressing XEgr-1-GR and treated with Dex. Premature activation does not occur following activin treatment, nor in samples expressing Xbra-GR, nor is it observed for the other
genes studied. The slightly premature activation ofmuscle-speciﬁc actin, at stage 12, is likely to be an indirect effect caused by the earlier activation of XMyoD. (C) XMyoD is activated
by exposure to XEgr-1 as late as stage 12, by which time competence to respond to activin has been lost. Animal pole regions were treated as in (A), except that treatment with
activin or Dex started at stage 8, 10 or 12, as indicated. (D–F) Ectopic activation of XEgr-1 causes misexpression of XMyoD in whole embryos. Xenopus embryos were injected at the
one-cell stage with RNA encoding ΔXEgr-1-GR (D) or XEgr-1-GR (E, F) and left untreated (E) or were treated with Dexamethasone (D, F) from stage 12. They were cultured to stage
22 and assayed for expression of XMyoD by in situ hybridization. Note that Dex treatment of embryos expressing XEgr-1-GR causes ectopic activation of XMyoD (F). (G) Activation of
XMyoD by Xbra requires XEgr-1 activity. Xenopus tropicalis animal caps were derived from embryos previously injected with mRNA encoding with Xbra-GR, ΔXEgr-1-GR or XEgr-1-
GR as indicated, as well as XtEgr-1 MO1 or 2 as indicated. Animal caps were treated with Dexamethasone at stage 8.5 and cultured to the equivalent of stage 14 before being assayed
for expression of XtMyoD. Note that Xbra-GR activation induces XtMyoD (second lane) and that this activation requires XtEGR-1 activity (third and fourth lanes). Co-expression of
XEgr-1GR rescues XtMyoD activation (sixth and seventh lanes).
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Fig. 8. Elk-1 induces expression of XMyoD via XEgr-1. Animal pole explants were derived
from Xenopus tropicalis embryos previously injected with mRNA (500 pg) encoding a
constitutively active (ca) form of Elk-1 together with control morpholino or XEgr-1 MO2.
Animal caps were cultured to the equivalent of stage 14 when they were assayed for
expression of XtEgr-1 or XtMyoD. caElk-1 activates expression of XtEgr-1, and this
activation is not inhibited by XtEgr-1 MO2 (A). Activation of XtMyoD, however, is
substantially inhibited in animal pole regions in which XtEgr-1 activity is diminished (B).
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the more effective (see Figs. 5T–AA), and use of this reagent revealed
that although there was little difference in levels of Xbra at earlier
stages (Figs. 5L–N and P–R), by stage 15 expression of Xbra was
elevated in embryos in which XEgr-1 function was inhibited,
particularly in the posterior region of the embryo (Figs. 5O and S).
This impression was conﬁrmed by analysis of Xtbra expression by
quantitative RT-PCR (Fig. 5X), and in situ hybridization and
quantitative RT-PCR experiments also demonstrated that XtmyoD is
down-regulated in such embryos (Figs. 5T–X). At later stages, loss of
XEgr-1 function caused anterior, dorsal and axial structures to
develop poorly, with impairment of both muscle and notochord
differentiation (Figs. 5Y–EE). These later defects are likely to be
indirect consequences of the earlier disruption of gene expression.
Together, these experiments show that loss of XtEgr-1 function
causes the up-regulation of Xtbra and the down-regulation of
XtMyoD. We went on to investigate the interactions between these
three genes by combined gain- and loss-of-function studies.
XEgr-1 is a direct repressor of Xbra
The experiments described above indicate that XEgr-1 is a
negative regulator of Xbra in the intact Xenopus embryo. Similar
results were obtained in experiments using isolated animal pole
regions: XEgr-1 caused a signiﬁcant decrease in the expression of Xbra
(data not shown, but see below), and of other genes such as goosecoid
(Fig. 6A) and Xvent-1 (data not shown), in response to both activin
and FGF. The gastrulation-like movements that occur in response to
activin were also inhibited by XEgr-1 (data not shown).
To ask whether XEgr-1 exerts these effects in a direct manner, we
fused the XEgr-1 open reading frame to the ligand binding domain of
the human glucocorticoid receptor to create XEgr-1-GR (Fig. 6B).
Fusion proteins of this sort remain inactive unless dexamethasone is
added to the medium (Kolm and Sive, 1995; Tada et al., 1997). A
derivative of XEgr-1-GR lacking the DNA binding zinc ﬁnger domain
and part of the transactivation domain was used as a control in these
experiments (Fig. 6B). This construct is expressed at similar levels to
XEgr-1-GR in in vitro transcription/translation reactions (Fig. 6C).
Experiments were performed in which animal pole regions were
derived from control-injected embryos or embryos that had previ-
ously been injected with RNA encoding XEgr-1-GR and were then
treated with combinations of activin, bFGF, cycloheximide and
dexamethasone. Such experiments demonstrated that XEgr-1-GR
can repress induction of Xbra by FGF (Fig. 6D) and by activin (Fig. 6E),
even in the presence of cycloheximide. Together, these observations
suggest that XEgr-1 acts directly on the Xbra promoter to repress its
expression.
XEgr-1 is a direct activator of XMyoD
The results described above indicate that XEgr-1 represses genes
such as Xbra that are expressed in the mesoderm of the Xenopus
embryo. In additional experiments, however, we observe that XEgr-1
can activate the expression of XMyoD in isolated animal pole regions
and that this activation occurs in a direct fashion (Fig. 7A). In doing so,
XEgr-1 acts downstream of Xelk-1 because although XEgr-1MO2 does
not prevent a constitutively active (ca) form of Elk-1 (Hill et al., 1994)
from inducing transcription of XtEgr-1 itself in isolated X. tropicalis
animal pole regions (Fig. 8A), it does inhibit activation of XtMyoD
(Fig. 8B).
Remarkably, XEgr-1 can cause premature activation of XMyoD at
mid blastula stage 8.5, before the gene is transcribed in the normal
embryo (Fig. 7B). This observation stands in contrast to many other
experiments in Xenopus, where the time of administration of a
stimulus does not affect the stage at which the response occurs
(Cooke and Smith, 1990). For example, activin treatment of animalpole regions causes the onset of gastrulation movements at stage 10.5
(Symes and Smith, 1987), as well as XMyoD transcription (Steinbach
et al., 1998), irrespective of the stage at which activin was
administered. Furthermore, the onset of cardiac actin gene expression
in animal pole regions always occurs around stage 12 irrespective of
the stage at which they were juxtaposed with vegetal pole tissue
(Gurdon et al., 1985).
Another timing phenomenon in Xenopus concerns the acquisition
and loss of competence: the ability of cells to respond to a stimulus
(Dale et al., 1985; Grainger and Gurdon, 1989; Green and Smith,
1990). The ability of the XMyoD gene in wild-type animal caps to
respond to activin is lost by stage 10 (Steinbach et al., 1997), but we
observe that the ability to respond to XEgr-1 persists at least until
stage 12 (Fig. 7C). These results further emphasise that XEgr-1 is a
direct regulator ofMyoD, as do the observations thatMyoD expression
(Figs. 5T–X) andmyogenesis (Figs. 5BB and CC) are down-regulated in
embryos injected with MOs targeted against XEgr-1 and that over-
expression of XEgr-1 causes ectopic XMyoD expression (Figs. 7D–F).
Although misexpression of XEgr-1 can activate XMyoD and
subsequently muscle-speciﬁc actin (Fig. 7B), it fails to induce other
myogenic regulatory factors such as Xmyf5 and it also fails to activate
pMesogenin-1, which regulates paraxial mesoderm formation. How-
ever, these genes do respond to Xbra and Activin (Fig. 7B and data not
shown), as described previously (Lin et al., 2003 and data not shown).
Xbra can also activate expression of XMyoD, but in contrast to XEgr-1
it cannot do so prematurely (Fig. 7B) and indeed it requires XEgr-1
function (Fig. 7G). Xbra may, however, play some direct role in
activating XMyoD (data not shown) and indeed a zebraﬁsh orthologue
of Xbra, Ntl, interacts with the MyoD regulatory region (Morley et al.,
2009). In the Discussion of this paper we ask how our results can be
integrated into a model for the action of FGF in mesoderm formation
in the early Xenopus embryo.
Discussion
The body plan of the early amphibian embryo is established during
late blastula and gastrula stages in response to signalling by members
of the TGF-β, FGF, BMP and Wnt families of signalling molecules. The
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network involving positive and negative autoregulation and coherent
and incoherent feed-forward loops (Alon, 2007; Casey et al., 1998;
Collavin and Kirschner, 2003; Loose and Patient, 2004; Pera et al.,
2003; Steinbach et al., 1998; Tanegashima et al., 2000). Although the
network is initiated by several distinct signalling molecules, the
present work emphasises that there is signiﬁcant cross talk between
their signal transduction pathways. Furthermore, detailed analysis of
the network described here reveals some surprising and counterin-Fig. 9. The positions of XElk-1, XSRF, XEgr-1, Xbra and XMyoD in the genetic regutuitive results that shed light upon the dynamics of mesoderm
formation.
Towards a genetic regulatory network for mesoderm formation
The results obtained in the course of these experiments, together
with data derived from the work of others, are summarised in Fig. 9A.
Networks of this sort are necessarily incomplete, but they provide a
valuable starting point for discussion and for designing futurelatory network activated by FGF in the Xenopus embryo. See text for details.
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sphere of the embryo cause the nuclear translocation of a Smad2/
Smad4 heteromer that interacts with speciﬁc co-activators to induce
the expression of genes such as Xbra and goosecoid. Goosecoid
encodes a transcriptional repressor, whose targets include Xbra. Xbra
encodes a transcriptional activator, amongst whose targets are eFGF
(Casey et al., 1998), although eFGF is also a direct target of TGF-β
signals (Fisher et al., 2002). Activation of eFGF by Xbra occurs through
the two regulatory elements 5′-TCACACCT-3′ and 5′-CCACACCT-3′
(Casey et al., 1998). Once activated by Xbra, eFGF participates in a
positive autoregulatory loop in which its secreted product induces
expression of Xbra through the MAP kinase pathway (and perhaps
through Elk-1; see Fig. 2P and Fig. 4I) (Gotoh et al., 1995; LaBonne et
al., 1995; Umbhauer et al., 1995).
XEgr-1: downstream of FGF and SRF
Another target of FGF signalling is XEgr-1. FGF causes the
phosphorylation of XElk-1 on serine 366 (Figs. 1D and E), and
phosphorylated XElk-1 then joins XSRF on the XEgr-1 promoter to
form a ternary complex that activates XEgr-1 expression (Fig. 4).
Although the role of Egr-1 in Xenopus has been little studied, over-
expression of SRF is known to interfere with mesoderm formation,
while its inhibition expands it (Panitz et al., 1998; Yun et al., 2007).
XEgr-1 is activated by SRF, so our observation that over-expression
of XEgr-1 inhibits expression of Xbra (Figs. 5A–D), a gene expressed
throughout the marginal zone, is consistent with these results, as is
the observation that inhibition of XEgr-1 activity elevates Xbra
(Figs. 5L–S, X). Similarly, over-expression of SRF inhibits muscle
differentiation in the Xenopus embryo (Yun et al., 2007), and the
same phenotype is observed following over-expression of XEgr-1
(Figs. 5H and I).
But as we discuss in more detail below, this cannot be the whole
story. FGF acts as a mesoderm-inducing factor and activates
expression of Xbra, so why should XEgr-1, one of its direct targets,
go on to inhibit Xbra? And if over-expression of XEgr-1 prevents
proper muscle differentiation in Xenopus, why should its loss function
have the same effect (Figs. 5BB and CC)?
XEgr-1: a key regulator of mesoderm formation
Our results show that XEgr-1 has two distinct effects. First, it is a
direct activator of XMyoD (Fig. 7A), and thereby an indirect
activator of muscle-speciﬁc actin. The direct nature of its activity
is emphasised by two surprising results. First, use of a hormone-
inducible version of XEgr-1 shows that it can cause the premature
activation of XMyoD (Fig. 7B). And second, use of the same
construct shows that it is able to activate XMyoD at stages when
cells are no longer competent to respond to the mesoderm-inducing
factor activin (Fig. 7C). Loss of XEgr-1 function in X. tropicalis
reduces XMyoD expression (Figs. 5T–X) while over-expression
activates it (Fig. 7), emphasising the primacy of XEgr-1 in regulating
XMyoD and controlling muscle formation during normal Xenopus
development.
The ability of XEgr-1 to override the mechanisms that ensure the
proper timing of gene expression in the Xenopus embryo is unusual
and is reminiscent of the effect of Smarcd, whose over-expression in
the zebraﬁsh embryo causes the premature activation of MyoD and
Myf5 (Ochi et al., 2008). Smarcd3 is a subunit of the SWI/SNF
chromatin-remodelling complex. Intriguingly, it interacts with Ntl,
the zebraﬁsh orthologue of Xbra and requires Ntl for its activity (Ochi
et al., 2008). This observation is of note when considered alongside
the second activity of XEgr-1: the down-regulation of genes such as
goosecoid, Xvent-1 and Xbra, which, in at least the case of Xbra,
appears to occur in a direct manner. This repression of Xbra by XEgr-1,
together with the fact that XEgr-1 can induce XMyoD at stage 8.5,before signiﬁcant transcription of Xbra occurs (Piepenburg et al.,
2004), suggests that XEgr-1 does not require Xbra to activate XMyoD.
Egr-1 was originally characterised as an activator of gene
expression (Lemaire et al., 1990), but more recently it has also been
shown to act as a repressor (Bahouth et al., 2002; Chapman and
Perkins, 2000;Wang et al., 2005).We do not yet know themechanism
by which XEgr-1 regulates its targets in Xenopus, although the X.
tropicalis MyoD promoter contains the sequence 5′-GCGGGGGCT-3′
with which human Egr-1 interacts to activate the expression of apo-
lipoptotein A1 (Kilbourne et al., 1995). We have detected no such
binding site in the Xenopus laevis (Latinkic et al., 1997) or X. tropicalis
Brachyury promoter and do not yet know how XEgr-1 represses Xbra
transcription.
Like XEgr-1, XMyoD and Xbra are expressed in the prospective
mesoderm and all three are activated by FGF signalling (Fisher et al.,
2002; Smith et al., 1991). The ability of XEgr-1 simultaneously to
activate XMyoD and to repress Xbra is thus rather counterintuitive. It
may be informative, however, to discuss them in terms of two
genetic circuits, both of which resemble incoherent feed-forward
loops (Alon, 2007; Mangan et al., 2006). In the ﬁrst motif (Fig. 9B),
eFGF induces the expression of both XEgr-1 and Xbra. Xbra then
induces expression of eFGF, but its transcription is down-regulated
by XEgr-1. This motif resembles an incoherent type 1 feed-forward
loop (Alon, 2007), with an additional component in which Xbra
activates eFGF. Two characteristics of the incoherent type 1 feed-
forward loop are that it can promote peaks of transcription following
the application of an inducer and also that it can accelerate the
transcriptional response of the network (Alon, 2007; Mangan et al.,
2006). The Xenopus embryo develops at 20–24 °C, at which
temperatures reaction rates may be one third of those at 37°C;
such genetic circuits may therefore be important in ensuring rapid
responses to inductive interactions.
The second motif (Fig. 9C) emphasises that XEgr-1 acts both as an
activator of XMyoD and as a repressor of Xbra. This motif also includes
an autocatalytic loop in which XMyoD regulates its own expression
(Steinbach et al., 1998) and a negative feedback loop in which Xbra
activates expression of XEgr-1 via induction of XeFGF and XEgr-1 then
represses Xbra. Under a scheme such as this Xbra is likely to
contribute little to the steady state expression level of XMyoD but
may be involved, albeit indirectly, in its activation (Alon, 2007).
Consistent with this suggestion, muscle development is only slightly
impaired in embryos in which Brachyury function is inhibited (Conlon
et al., 1996), and in zebraﬁsh ntl embryos the later phase of MyoD
expression appears normal, while the early phase is absent or delayed
(Weinberg et al., 1996).
Conclusions
Our results illustrate the complexity of mesoderm formation in the
early amphibian embryo and emphasise the importance of under-
standing the regulatory networks that underlie early developmental
decisions. Results that are apparently counterintuitive might be
explained by considering temporal aspects of development and the
contributions of different proteins to the initial activation of genes and
to the steady state situation.
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